DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Nanomedicine Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering.
The Nanomedicine Market to Grow at a CAGR of 17.1% During the Forecast Period 2017-2023 to Aggregate $392.80 Billion By 2023.
The nanomedicine market is analyzed based on two segments - therapeutic applications and regions.
The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.
Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas.
Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.
Market Dynamics
Drivers
- Emergence of nanorobotics
- Applications and advantages of nanomedicine in various healthcare segments
- Reasonable investments in R&D
- Increased support from governments
Restraints
- Long approval process and stringent regulations
- Problems regarding nanoscale manufacturing
- Risks related to nanomedicines
- Undefined regulatory standards
Opportunities
- Aging population with chronic care needs
- Population and income growth in emerging countries
Key Players:
- Merck & Co. Inc.
- Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Novartis AG
- Amgen Inc
- Pfizer Inc.
- Eli Lilly and Company
- Sanofi
- Nanobiotix SA
-
UCB SA
Key Topics Covered:
1 Industry Outlook
2 Report Outline
3 Market Snapshot
4 Market Outlook
5 Market Characteristics
6 Trends, Roadmap and Projects
7 Types: Market Size and Analysis
8 Trending Nanomedicines
9 Regions: Market Size and Analysis
10 Vendor Scenario
11 Vendor Profiles
12 Global Generalist
13 Companies to Watch for
14 Market Landscape
For more information about this report visit http://www.researchandmarkets.com/research/2bv34j/global
